These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 9352138)

  • 1. CYP2D6 Hhal genotype and the neuroleptic malignant syndrome (NMS).
    Iwahashi K; Nakamura K; Suwaki H; Tsuneoka Y; Ichikawa Y
    Clin Chim Acta; 1997 Sep; 265(1):143-4. PubMed ID: 9352138
    [No Abstract]   [Full Text] [Related]  

  • 2. CYP2D6 HhaI genotype and the neuroleptic malignant syndrome.
    Iwahashi K; Yoshihara E; Nakamura K; Ameno K; Watanabe M; Tsuneoka Y; Ichikawa Y; Igarashi K
    Neuropsychobiology; 1999; 39(1):33-7. PubMed ID: 9892857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report.
    Kato D; Kawanishi C; Kishida I; Furuno T; Matsumura T; Hasegawa H; Suzuki K; Hirayasu Y
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):504-7. PubMed ID: 16048458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity.
    Kawanishi C; Furuno T; Onishi H; Sugiyama N; Suzuki K; Matsumura T; Ishigami T; Kosaka K
    Psychiatr Genet; 2000 Sep; 10(3):145-7. PubMed ID: 11204351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B.
    Kawanishi C; Hanihara T; Maruyama Y; Matsumura T; Onishi H; Inoue K; Sugiyama N; Suzuki K; Yamada Y; Kosaka K
    Psychiatr Genet; 1997; 7(3):127-9. PubMed ID: 9323326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome.
    Kato D; Kawanishi C; Kishida I; Furuno T; Suzuki K; Onishi H; Hirayasu Y
    Eur J Clin Pharmacol; 2007 Nov; 63(11):991-6. PubMed ID: 17701031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome.
    Kawanishi C; Shimoda Y; Fujimaki J; Onishi H; Suzuki K; Hanihara T; Sugiyama N; Kosaka K
    J Neurol Sci; 1998 Sep; 160(1):102-4. PubMed ID: 9804127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome P-450 2D6 gene polymorphism is not associated with neuroleptic malignant syndrome.
    Ueno S; Otani K; Kaneko S; Koshiro K; Kondoh K; Kotani Y; Sano A
    Biol Psychiatry; 1996 Jul; 40(1):72-4. PubMed ID: 8780858
    [No Abstract]   [Full Text] [Related]  

  • 9. Neuroleptic malignant syndrome in an adolescent with CYP2D6 deficiency.
    Butwicka A; Krystyna S; Retka W; Wolańczyk T
    Eur J Pediatr; 2014 Dec; 173(12):1639-42. PubMed ID: 24253372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation.
    Ochi S; Kawasoe K; Abe M; Fukuhara R; Sonobe K; Kawabe K; Ueno S
    Gen Hosp Psychiatry; 2011; 33(6):640.e1-2. PubMed ID: 21749835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of association in Japanese patients between neuroleptic malignant syndrome and the TaqI A polymorphism of the dopamine D2 receptor gene.
    Kishida I; Kawanishi C; Furuno T; Matsumura T; Hasegawa H; Sugiyama N; Suzuki K; Yamada Y; Kosaka K
    Psychiatr Genet; 2003 Mar; 13(1):55-7. PubMed ID: 12605103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
    Zivković M; Mihaljević-Peles A; Sagud M; Silić A; Mihanović M
    Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome.
    Suzuki A; Kondo T; Otani K; Mihara K; Yasui-Furukori N; Sano A; Koshiro K; Kaneko S
    Am J Psychiatry; 2001 Oct; 158(10):1714-6. PubMed ID: 11579007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of association between neuroleptic malignant syndrome and polymorphisms in the 5-HT1A and 5-HT2A receptor genes.
    Kawanishi C; Hanihara T; Shimoda Y; Suzuki K; Sugiyama N; Onishi H; Miyakawa T; Yamada Y; Kosaka K
    Am J Psychiatry; 1998 Sep; 155(9):1275-7. PubMed ID: 9734554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
    Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
    Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene.
    Kishida I; Kawanishi C; Furuno T; Kato D; Ishigami T; Kosaka K
    Mol Psychiatry; 2004 Mar; 9(3):293-8. PubMed ID: 15094790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphism of CYP2D6 in the Japanese population.
    Chida M; Yokoi T; Kosaka Y; Chiba K; Nakamura H; Ishizaki T; Yokota J; Kinoshita M; Sato K; Inaba M; Aoki Y; Gonzalez FJ; Kamataki T
    Pharmacogenetics; 1999 Oct; 9(5):601-5. PubMed ID: 10591540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation frequencies of the cytochrome CYP2D6 gene in Parkinson disease patients and in families.
    Lucotte G; Turpin JC; Gérard N; Panserat S; Krishnamoorthy R
    Am J Med Genet; 1996 Jul; 67(4):361-5. PubMed ID: 8837703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of relation between genetic polymorphism of cytochrome P-450IID6 and sporadic idiopathic Parkinson's disease.
    Bordet R; Broly F; Destée A; Libersa C; Lafitte JJ
    Clin Neuropharmacol; 1996 Jun; 19(3):213-21. PubMed ID: 8726540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphism of cytochrome P450 2D6 in idiopathic Parkinson disease and diffuse Lewy body disease.
    Bordet R; Broly F; Destee A; Libersa C
    Clin Neuropharmacol; 1994 Oct; 17(5):484-8. PubMed ID: 9316701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.